Recent News

Share
and/or
Upcoming Seminars and Events

View upcoming seminars and events.

Learn more
531 News Items found
Therapeutic Cloning Treats Parkinson's Disease in Mice

Research led by investigators at Memorial Sloan Kettering Cancer Center has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson's disease in mice.
Researchers Identify New Genetic Marker for Breast Cancer

An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
Pictured: James Allison
James Allison Elected to the Institute of Medicine

James P. Allison, Chair of the Immunology Program in the Sloan Kettering Institute, has been elected a member of the Institute of Medicine.
Lorenz Studer
Team Creates Muscle Cells from Embryonic Stem Cells

A team of Memorial Sloan Kettering investigators has reported for the first time a novel strategy to coax human embryonic stem cells (HESCs) to develop into cells that could potentially be used to repair the musculoskeletal system, including bone, cartilage, and muscle.
Pictured: Johanna Joyce
Johanna Joyce Named to Geoffrey Beene Chair

Johanna Joyce, of the Sloan Kettering Institute's Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair.
Novel Regulation of the Common Tumor Suppressor PTEN

Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of <i>PTEN</i> function. The findings from two related studies are published in the January 12 issue of <i>Cell</i>.
Samuel Danishefsky
Chemist Samuel Danishefsky Wins Trio of Awards

Memorial Sloan Kettering Cancer Center chemist Samuel J. Danishefsky will be honored with three major awards this spring. Dr. Danishefsky is the incumbent of a Eugene W. Kettering Chair and a member of the Molecular Pharmacology and Chemistry Program in the Sloan Kettering Institute.
Chemist Samuel Danishefsky (left) and pharmacologist Ting-Chao Chou have collaborated closely on the study of epothilone drugs.
Finding Cancer Treatments in Nature

From antibiotics to painkillers to cancer drugs, many molecules found in nature have proven to be remedies for human disease. At Memorial Sloan Kettering, a handful of drugs now in clinical trials have been derived from sources ranging from microorganisms to plants to marine creatures. The theory behind the development of drugs from natural products is that these molecules inherently have some kind of biological function, and that function can be enhanced and exploited to develop effective treatments for patients.
Integrin Receptor Protein Found to Contribute To Tumor Angiogenesis

Scientists at Sloan Kettering Institute have discovered that the &#945;6&szlig;4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity of the &#945;6&szlig;4 subunit of this integrin on vascular cells, researchers found they could slow the growth of tumors.
Thomas Kelly
Thomas Kelly Wins General Motors Cancer Research Award

In recognition of his contributions in basic science related to cancer research, Sloan Kettering Institute Director Thomas J. Kelly has been awarded the 2004 Alfred P. Sloan, Jr. Prize by the General Motors Cancer Research Foundation.